Skip to main content
. Author manuscript; available in PMC: 2014 Aug 25.
Published in final edited form as: Cancer Gene Ther. 2011 Aug 26;18(12):850–858. doi: 10.1038/cgt.2011.54

Figure 7. Effects of pDC, Treg, and MDSC depletion on immunization in CEA-Tg mice.

Figure 7

CEA-Tg mice were immunized with rAAV-CEA on day 1 and ODN1826 (ODN) on days 15 and 17. Anti-CD25, anti-Gr1, or control IgG antibody was given i.p. on days 13, 15, and 17; anti-PDCA-1 i.p. on days 13 and 15. Sera and spleen cells were harvested on day 22. (A) CEA-specific Th1/Th2/Th17 cytokine release was assessed by CBA. Data represent means ± SD, n = 3 mice per group. * = P < 0.05 versus IgG control. (B) CEA-specific IgG antibody was measured by ELISA. Data represent means ± SD, n = 3 mice per group. * = P < 0.05 versus IgG control. (C) CEA-Tg mice were immunized with rAAV-CEA, anti-PDCA-1, CD25, Gr1, or control (IgG) antibody, and ODN as above and challenged with MC38-CEA tumor cells on day 21 (day 0 on graph). Data are presented as means ± SEM, n = 6 mice per group.